productssinovac biotech ltd home  english español about sinovac mission statement company history facilities strategic partners products human vaccines materials download faqs research  development rd strategy rd pipeline investor relations company profile corporate governance stock information press releases financial reports sec filings events  presentations agm summary investor kit analyst coverage investor faq contact ir newsroom press releases contact us contact us products human vaccines inlive healive bilive anflu panflu panflu materials download faqs inlive healive bilive anflu locationhome products human vaccines inlive inlive is an original preventive vaccine in the world independently developed by sinovac biotech ltd which is mainly used to prevent the handfootmonth diseasehfmd caused by enterovirus type details healive healive is the first inactivated hepatitis a vaccine developed in china by chinese scientists at sinovac which retained the intellectual property rights it brought to an end an era in which china didetails bilive bilive® is the first and currently only combined inactivated hepatitis a and b vaccine developed by chinese scientists the rd and clinical trial period for bilive was completed in only four years details anflu sinovac commenced development of its split influenza vaccine in  the preclinical research was completed in  the result of clinical trial for anflu showed that it is well tolerated in childrdetails panflu panflu® is an inactivated hn influenza avian flu vaccine that was approved by state food and drug administration in april  this product was codeveloped by sinovac biotech co ltd and the chdetails panflu panflu ®is the first influenza a hn vaccine to be approved in the world and in china as the state food and drug administration granted approval in september  details pipeline generic vaccines innovative vaccines investor relations financial reports stock information site map contact us rss copyright   sinovac biotech ltd all rights reserved add no  shangdi xi road haidian district beijing prc  supported by elongtian sinovac biotech ltd – ordinar sva sees new week high finance dailydaily markets commodities personal finance and economic newssinovac biotech ltd – ordinar sva sees new week high july   by ted blackburn tweet         advertisement the company is now up from yesterday’s close of  company shares last traded at  slightly over the  day moving average which is  and which is marginally over the  day moving average of  the  day moving average went up by  and the  day average moved up  traders are more bearish lately if you take into consideration the motion in short interest the stock experienced a rise in short interest from may   to may   of  short shares grew  over that timeframe with short interest at  and short average daily volume at  days to cover is  and the short interest percentage is  as of may  sinovac biotech ltd sinovac launched on march   is a holding company the company is a biopharmaceutical company that focuses on the research development manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis a hepatitis b seasonal influenza haemagglutinase neuraminidase hn and influenza a hn pandemic influenza and mumps the business’s pipeline consists of vaccine candidates in the clinical and preclinical development phases in china the company is involved in the sales marketing manufacturing and development of vaccines for infectious disease the company is involved in developing various products including healive bilive anflu panflu whole viron pandemic influenza vaccine split viron pandemic influenza vaccine panflu rabend mumps vaccine enterovirus  ev vaccine pneumococcal polysaccharide vaccine pneumococcal conjugate vaccine rubella vaccine varicella vaccine and sabin inactivated polio vaccine         advertisement the following firms have also recently changed their position in sva as of the end of the quarter two sigma investments lp had bought a total of  shares growing its holdings by  the value of the total investment in sinovac biotech ltd – ordinar went from  to  increasing  quarter to quarter invesco ltd reduced its ownership by selling  shares a decrease of  invesco ltd claims  shares valued at  the total value of its holdings decreased  state street corp trimmed its holdings by shedding  shares a decrease of  as of  state street corp now controls  shares with a value of  the value of the position overall is down by  two sigma advisers lp bolstered its stake by buying  shares an increase of  from  to  two sigma advisers lp owns  shares worth  the total value of its holdings increased  on march  the stock rating was upgraded to “overweight” from “” in an announcement from morgan stanley         advertisement tweetrevenue generating websites kimball electronics inc nasdaqke stock traded much higher than its  day averagekinder morgan inc nysekmi stock closed  above its  day averagekulicke and soffa industries i nasdaqklic stock closed much higher than its  day moving averagekite pharma inc nasdaqkite stock traded  above its  day averagekeysight technologies inc nysekeys closed much higher than its  day moving averagekorea electric power corporatio nysekep closed  above its  day averagekemet corporation new nysekem closed much higher than its  day moving average markets economy peertopeer loans growing in popularity among consumersincrease in young american adults not owning credit cards for various reasons credit  loans monday’s interest rates for home mortgages at wells fargo bmo harris jul  wells fargo year frms are being quoted at  at wells fargo nysewfc carrying an apr of   the best  year fha … read more categories breaking technology auto health personal finance economy mortgage about fi daily home staff privacy policy contact us accessibility terms of use reuters business news oil gains ahead of producer meeting nigeria libya output in focusasian shares slip as risk appetite ebbs dollar sulksblackstone in talks to buy  percent of israel cyber firm nso reportaustralian regulator investigating takata airbag recall after deathchinas debt specter could haunt feds policy meetings sinovac biotech ltd enters into definitive agreement for goingprivate transaction  pressreleasepoint jump to navigation pressreleasepoint free press release distribution website main menubusiness technology health education entertainment environment hospitality human interest social issues labor law politics religion sports disaster war conflict weather secondary menuusa canada australia uk india south africa new zealand singapore more countries pressreleasepoint mainpressreleasepoint main pressreleasepoint free submit press releasesubmit press release submit free press release press release dos and donts press release how to free pr website list pr resourcespr articles ebooks pr agencies media directory pr videos search pr sites social book marking sites press releasesall press release most viewed pr today popular pr  days popular pr  days popular pr all time pr most liked on fb  days popular pr on fb user press release interesting press release priority release page our servicessubmit press release  free pr sites track and publish press release distribute press release to media press release writing service free trial submit to  pr sites about uspressreleasepoint frequently asked questions faq site analytics and traffic graph copyright privacy policy contact us sinovac biotech ltd enters into definitive agreement for goingprivate transaction view devel posted june th  for sinovac biotech printerfriendly version beijing june      sinovac biotech ltd nasdaq sva “sinovac” or the “company” a leading provider of biopharmaceutical products in china today announced that it has entered into a definitive amalgamation agreement the “amalgamation agreement” with sinovac cayman limited “parent” and sinovac amalgamation sub limited “amalgamation sub” a wholly owned subsidiary of parent pursuant to which sinovac will be acquired by parent in a transaction valued at approximately us million   pursuant to the amalgamation agreement parent will acquire the company for cash consideration equal to us per common share of the company each a “share”  this represents a premium of  and  respectively over the company’s  and trading day volumeweighted average price as quoted by nasdaq prior to the company’s announcement on february   that it had received a nonbinding “goingprivate” proposal from mr weidong yin the chairman president and chief executive officer of the company and saif partners iv lp “saif” andor its affiliates to acquire all of the outstanding shares not already owned by them   the consideration to be paid to holders of shares pursuant to the amalgamation agreement also represents an increase of approximately  from the original us per share offer price in the “goingprivate” proposal announced on february     immediately following the consummation of the transactions contemplated by the amalgamation agreement parent will be beneficially owned by a consortium the “buyer consortium” comprising mr yin saif cbridge healthcare fund ii lp “cbridge capital” advantech capital lp “advantech capital” vivo capital fund viii lp and vivo capital surplus fund viii lp together with vivo capital fund viii lp “vivo capital”  as of june   the members of the buyer consortium beneficially own in the aggregate approximately  of the issued and outstanding shares   subject to the terms and conditions of the amalgamation agreement at the effective time of the amalgamation amalgamation sub will be amalgamated with and into the company with the company continuing as the surviving corporation and a wholly owned subsidiary of parent the “amalgamation” and each of the shares issued and outstanding immediately prior to the effective time of the amalgamation will be canceled in consideration for the right to receive us per share in cash without interest and net of any applicable withholding taxes except for i  shares held by mr yin and  shares held by saif collectively the “rollover shareholders” ii shares held by parent parent’s affiliates the company or any of the company’s subsidiaries which shares in each case will be canceled without payment of any consideration or distribution therefor and iii shares owned by holders who have validly exercised and not effectively withdrawn or lost their rights to dissent from the amalgamation in accordance with the provisions of section  of the international business corporations act cap  of the revised laws of antigua and barbuda as consolidated and revised the “ibca” which shares will be canceled at the effective time of the amalgamation for the right to receive the fair value of such shares determined in accordance with the provisions of section  or section  of the ibca as applicable   the buyer consortium intends to fund the amalgamation through a combination of cash contributions from cbridge capital advantech capital and vivo capitalor their respective affiliates pursuant to equity commitment letters   the company’s board of directors acting upon the unanimous recommendation of the special committee formed by the board of directors the “special committee” unanimously approved the amalgamation agreement and the transactions contemplated by the amalgamation agreement including the amalgamation and resolved to recommend that the company’s shareholders authorize and approve the amalgamation agreement and the transactions contemplated by the amalgamation agreement including the amalgamation  the special committee which is composed solely of independent directors of the company who are unaffiliated with parent amalgamation sub or any member of the buyer consortium or management of the company exclusively negotiated the terms of the amalgamation agreement with the buyer consortium with the assistance of its independent financial and legal advisors   the amalgamation which is currently expected to close during the second half of  is subject to customary closing conditions including approval by an affirmative vote of holders of shares representing at least twothirds of the shares present and voting in person or by proxy as a single class at a meeting of the company’s shareholders which will be convened to consider the authorization and approval of the amalgamation agreement and the transactions contemplated by the amalgamation agreement including the amalgamation and the other closing conditions specified in the amalgamation agreement  as of june   the rollover shareholders beneficially own in the aggregate approximately  of the issued and outstanding shares  pursuant to a support agreement among the rollover shareholders parent and sinovac holding cayman limited the sole shareholder of parent the rollover shareholders have agreed to vote all their shares in favor of the authorization and approval of the amalgamation agreement and the transactions contemplated by the amalgamation agreement including the amalgamation  if completed the amalgamation will result in the company becoming a privatelyheld company and the shares will no longer be listed on nasdaq   duff  phelps llc is serving as financial advisor to the special committee  weil gotshal  manges llp is serving as us legal counsel to the special committee leslieann brissett legal services is serving as antigua and barbuda legal counsel to the special committee and haiwen  partners is serving as prc legal counsel to the special committee   latham  watkins llp is serving as us legal counsel to the company and delaney law is serving as antigua and barbuda legal counsel to the company   lazard is serving as financial advisor to the buyer consortium  kirkland  ellis is serving as us legal counsel to mr yin and the buyer consortium and roberts  co is serving as antigua and barbuda legal counsel to the buyer consortium  skadden arps slate meagher  flom llp is serving as us legal counsel to cbridge capital and advantech capital  ropes  gray llp is serving as us legal counsel to vivo capital   additional information about the transaction   the company will furnish to the securities and exchange commission the “sec” a report on form k regarding the proposed transactions described in this announcement which will include as an exhibit thereto the amalgamation agreement  all parties desiring details regarding the transactions contemplated by the amalgamation agreement including the amalgamation are urged to review these documents which will be available at the sec’s website httpwwwsecgov    in connection with the amalgamation the company will prepare and mail a proxy statement to its shareholders in addition certain participants in the amalgamation will prepare and mail to the company’s shareholders a schedule e transaction statement that will include the proxy statement these documents will be filed with or furnished to the sec investors and shareholders are urged to read carefully and in their entirety these materials and other materials filed with or furnished to the sec when they become available as they will contain important information about the company the transactions contemplated by the amalgamation agreement and related matters in addition to receiving the proxy statement and schedule e transaction statement by mail shareholders also will be able to obtain these documents as well as other filings containing information about the company the amalgamation and related matters without charge from the sec’s website httpwwwsecgov or at the sec’s public reference room at  f street ne room  washington dc   in addition these documents can be obtained without charge by contacting the company at the following address andor phone number   sinovac biotech ltd no  shangdi xi road haidian district beijing people’s republic of china phone     the company and certain of its directors executive officers and other members of management and employees may under sec rules be deemed to be “participants” in the solicitation of proxies from shareholders with respect to the amalgamation information regarding the persons or entities who may be considered “participants” in the solicitation of proxies will be set forth in the proxy statement and schedule e transaction statement relating to the amalgamation when it is filed with the sec additional information regarding the interests of such potential participants will be included in the proxy statement and schedule e transaction statement and the other relevant documents filed with the sec when they become available   this announcement is neither a solicitation of proxy an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that may be made with the sec should the amalgamation proceed   safe harbor statement   this announcement may include certain statements that are not descriptions of historical facts but are forwardlooking statements  these statements are made under the “safe harbor” provisions of the us private securities litigation reform act of   these forwardlooking statements can be identified by terminology such as “will”“expects”“anticipates”“future”“intends”“plans”“believes”“estimates” and similar statements  forwardlooking statements involve risks uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements  potential risks and uncertainties include but are not limited to uncertainties as to how the company’s shareholders will vote at the meeting of shareholders the possibility that competing offers will be made the possibility that various closing conditions to the amalgamation may not be satisfied or waived and other risks and uncertainties discussed in sinovac’s filings with the sec as well as the schedule e transaction statement and the proxy statement to be filed by the company in connection with the amalgamation  sinovac does not undertake any obligation to update any forwardlooking statement except as required under applicable law   about sinovac   sinovac biotech ltd is a chinabased biopharmaceutical company that focuses on the research development manufacturing and commercialization of vaccines that protect against human infectious diseases sinovacs product portfolio includes vaccines against enterovirus or ev hepatitis a and b seasonal influenza hn pandemic influenza avian flu hn influenza swine flu and mumps the ev vaccine an innovative vaccine developed by sinovac against hand foot and mouth disease caused by ev was commercialized in china in  in  sinovac was the first company worldwide to receive approval for its hn influenza vaccine which it has supplied to the chinese governments vaccination campaign and stockpiling program the company is also the only supplier of the hn pandemic influenza vaccine to the government stockpiling program the company is currently developing a number of new products including a sabinstrain inactivated polio vaccine pneumococcal polysaccharides vaccine pneumococcal conjugate vaccine and varicella vaccine sinovac primarily sells its vaccines in china while also exploring growth opportunities in international markets the company has exported select vaccines to over  countries in asia and south america  for more information please visit the company’s website at wwwsinovaccom search pr sites printerfriendly version copy this html code to your websiteblog to embed this press release a hrefhttpwwwpressreleasepointcomsinovacbiotechltdentersdefinitiveagreementgoingprivatetransaction classactivesinovac biotech ltd enters into definitive agreement for goingprivate transactiona comments post new comment your name  emailnot displayed  math test to stop spam      comment  to prevent automated spam submissions leave this field empty this press release is licensed under a creative commons attribution  unported license read full copyright information here like this site on facebook distribute press release just  post your press release to list of  free press release websites effortlessly publish all your press releases with our automated pickup and submission service write a basic press release for  search search this site tags business financehealth medical pharmaboard of directorseconomyfinancial servicesmerger and acquisitionmergers and acquisitionsnasdaqpharmaceuticalsproxy statementsec filingsswine fluvaccinationwashington dcbeijingunited statestaiwanantigua and barbudastructureconsolidationcorporate lawlegal entitiessinovac biotechsubsidiarybiopharmaceuticalbiopharmaceutical productsowned subsidiaryadvantech capital lpann brissett legal servicesbridge capitalcbridge healthcare fund ii lpduff  phelps llchaiwen amp partnerskirkland  ellislatham  watkins llplazardroberts  coropes  gray llpsaif partners iv lpsinovac cayman limitedsinovac biotech ltdsinovac holding cayman limitedskadden arps slate meagher  flom llpvivo capital fund viii lpvivo capital surplus fund viii lpweil gotshal  manges llpavian fluchinese governmentdelaney lawfoot and mouth diseasehn influenzahn pandemic influenzahaidian districthepatitis ahuman infectious diseasesleslieann brissettmumpspolio vaccineseasonal influenzasecurities and exchange commissionspecial committeevaricella vaccineweidong yin user login loginregister username or email  password  remember me forgot userid  email id request new password to prevent automated spam submissions leave this field empty like  share this page google plus one tweet widget forward delicious digg stumbleupon technorati reddit newsvine diigo page traffic sinovac biotech press release  sinovac biotech ltd enters into definitive agreement for goingprivate transaction sinovac biotech announces receipt of nasdaq letter sinovac responds to recent report sinovac announces results of  annual general meeting of shareholders sinovac schedules  annual meeting of shareholders sinovac special committee engages financial and legal advisors sinovac adopts shareholder rights plan and declares dividend distribution of preferred share purchase rights sinovac announces receipt of competing nonbinding going private proposal sinovac announces receipt of a preliminary nonbinding proposal to acquire the company and formation of independent special committee sinovac obtains new drug certificate and production license for ev vaccine more sinovac biotech press release free press release distribution website write press release submit press release distribute press release september st deadline alert gpm reminds investors of looming deadline in the class action lawsuit against sinovac biotech ltd  traders log in email password remember forgot password  become a member for free sign up sign up new membersign up for free new customerdiscover our portfolios united states united kingdom france deutschland schweiz de suisse fr settings dynamic quotes  offon markets equities north americaeuropeasiaoceaniamiddle east� more equities indexes dow jonessp nasdaq tsx compftse � more indexes currency  forex eur  usdgbp  usdusd  jpyusd  cadaud  usd� more currencies commodities goldcrude oil wticrude oil brentsilverplatinum� more commodities news latest news companiesmarketseconomycurrency  forexcommoditiesinterest ratesbusiness leadersfinancial calendareconomic calendar listed company analyst recorumorsiposcapital markets transactionsnew contractsprofits warningsappointmentspress releaseseventscorporate actions sector news energybasic materialsindustrialsconsumer cyclicalconsumer noncyclicalfinancialshealthcaretechnologytelecommunications servicesutilities analysis all analysiscommentariesindex analysisstock trading strategiescommodity analysisforex analysis stock picks all stock picks portfolios my portfolio virtual portfolios traders portfolios european portfoliousa portfolioasian portfolio screeners market screener homefundamental analyse top investor ratingtop trading ratingtop consensusgrowth stocksyield stockslow valuations technical analysis oversold stocksoverbought stocksclose to resistancesclose to supportsaccumulation phasemost volatile stocks watchlists my watchlists watchlists top lists yield stocksgrowth stocksundervalued stocks top  flop top news most read newshot news top fundamentals top capitalizationtop yieldtop pertop consensustop fundamentals top technicals top rsiunusual volumestop gapstop stim top movers top usatop canadatop uktop germanytop europetop asia tools market screenerdynamic chartfinancial calendareconomic calendarsector researchcurrency converter our services premium accessdiscover our services traders homepage    equities    nasdaq    sinovac biotech ltd    sva   agpw sinovac biotech ltd sva add to my list    mes derni�res consultmost popular manage my lists  delayed     pm  usd     the klein law f  reminds investors of a class action filed on behal  the klein law f  announces a class action filed on behalf of sinova  sva the law offices of vincent wong reminds investors of commence summaryquoteschartsnewscalendarcompanyfinancials news summarymost relevantall newssector newstweets september st deadline alert gpm reminds investors of looming deadline in the class action lawsuit against sinovac biotech ltd    pm cest send by mail  last name  name  from  to  you can enter multiple email addresses separated by commas message  required fields glancy prongay  murray llp “gpm” reminds investors of the september   deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased sinovac biotech ltd “sinovac” or the “company” nasdaq sva securities between april   to may   inclusive the “class period” sinovac investors have until september   to file a lead plaintiff motion in this class action to obtain information or participate in the class action please visit the sinovac page on our website at httpwwwglancylawcomcasesinovacbiotechltd sinovac is a chinese biopharmaceutical company that engages in the research development manufacture and commercialization of vaccines against hepatitis a hepatitis b seasonal influenza hn and hn pandemic influenza and mumps on december   a report was published on seekingalphacom claiming that sinovac’s chairman and ceo weidong ying bribed a member of the chinese food and drug administration in connection with its vaccine clinical trial and approval on this news the company’s share price declined thereby injuring investors then on may   the company issued a press release disclosing that the sec notified the company of an enforcement inquiry related to the matters discussed in the seekingalphacom report and that the sec issued a subpoena requesting documents related to the company’s internal investigation into the matter on this news the company’s share price fell  on may   thereby injuring investors the complaint filed in this class action alleges that throughout the class period defendants made materially false andor misleading statements andor failed to disclose that  defendant weidong yin sinovac’s chairman and ceo bribed a member of the chinese food and drug administration to assist sinovac’s vaccine clinical trial and approval  such conduct would subject sinovac to heightened regulatory scrutiny and  as a result sinovac’s public statements were materially false and misleading at all relevant times follow us for updates on twitter twittercomgpmllp if you purchased shares of sinovac during the class period you may move the court no later than september   to request appointment as lead plaintiff in this putative class action lawsuit to be a member of the class action you need not take any action at this time you may retain counsel of your choice or take no action and remain an absent member of the class action if you wish to learn more about this class action or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit please contact lesley portnoy esquire of gpm  century park east suite  los angeles california  at  tollfree at  by email to shareholdersglancylawcom or visit our website at wwwglancylawcom if you inquire by email please include your mailing address telephone number and number of shares purchased this press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules view source version on businesswirecom httpwwwbusinesswirecomnewshomeen � business wire   latest news on sinovac biotech ltd  sinovac biotech ltd  khang  khang llp announces securities class action lawsu  the klein law firm  reminds investors of a class action filed on behalf of sino  sinovac biotech ltd  lundin law pc announces securities class action lawsuit a  the klein law firm  announces a class action filed on behalf of sinovac biotech  sinovac biotech ltd  khang  khang llp announces securities class action lawsu  sva the law offices of vincent wong reminds investors of commencement of a cl  sinovac biotech ltd  lundin law pc announces securities class action lawsuit a  sva the law offices of vincent wong notifies investors of commencement of a c  september st deadline alert  gpm reminds investors of looming deadline in the   sinovac biotech ltd  khang  khang llp announces securities class action lawsu more news news from seekingalpha  week in review  sinovacs privatization offer draws  million outside bid  premarket gainers as of    am  risk arbitrage today  rite aid hope for the best expect the worst  sinovac bio to go private in m transaction  healthcare gainers  losers as of    am chart sinovac biotech ltd duration  auto  months  months  months  months  year  years  years  years max period  day week fullscreen chart technical analysis trends sinovac biotech ltd short termmidtermlong termtrendsbullishbullishbullish technical analysis income statement evolution please enable javascript in your browsers settings to use dynamic charts more financials managers nametitlewei dong yin chairman president ceo  secretary nan wang chief financial officer  vice president qiang gao vice presidentresearch  development yuk lam lo independent director jue lee independent director more about the company sector and competitors st jancapitalization m sinovac biotech ltd biogen  csl limited  alexion pharmaceuticals  grifols sa  biomarin pharmaceutical  more results traderscom marketsnewsanalysisstock picksportfoliosscreenerswatchliststop  floptoolsour servicesabout surperformance sascontact usadvertiselegal informationsabout usstay connected facebooktwitterpartners b�rse aktien kurse und nachrichtenbest tweets copyright �  surperformance all rights reserved slave sinovac biotech ltd home  english español about sinovac mission statement company history facilities strategic partners products human vaccines materials download faqs research  development rd strategy rd pipeline investor relations company profile corporate governance stock information press releases financial reports sec filings events  presentations agm summary investor kit analyst coverage investor faq contact ir newsroom press releases contact us contact us investor relations financial reports  investor kit  products  pipeline products inlive healive bilive anflu panflu panflu pipeline sinovacs rd focuses on two aspects original v press releases company news sinovac biotech ltd enters into definit sinovac biotech announces receipt of nas sinovac reports announces filing extensi sinovac amends shareholder rights plan sinovac responds to recent report  sinovac presents on “vaccine world mena  sinovac attended the third open innovati  media report congratulations inoculat  media report hn vaccine trials urged  xiaoya chen vice minister of ministry o site map contact us copyright   sinovac biotech ltd all rights reserved add no  shangdi xi road haidian district beijing prc  supported by elongtian sinovac biotech ltd  product pipeline review   infomarketreportscentercom  us x login sign up facebook twitter linkedin google  mrc blog youtube sinovac biotech ltd  product pipeline review   home  pharmaceuticals  global markets direct  sinovac biotech ltd  product pipeline review   report details sinovac biotech ltd  product pipeline review   sku gmdaug category pharmaceuticals publisher global markets direct pages  published aug skugmdaug categorypharmaceuticals publisherglobal markets direct pages published onaug request discount pay by wireinvoice description table of content list of figures request sample description sinovac biotech ltd  product pipeline review   summary global markets directs sinovac biotech ltd  product pipeline review   provides an overview of the sinovac biotech ltds pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of sinovac biotech ltds complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of sinovac biotech ltd including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of sinovac biotech ltds human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the sinovac biotech ltds pipeline products reasons to buy  evaluate sinovac biotech ltds strategic position with total access to detailed information on its product pipeline  assess the growth potential of sinovac biotech ltd in its therapy areas of focus  identify new drug targets and therapeutic classes in the sinovac biotech ltds rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of sinovac biotech ltd and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of sinovac biotech ltd  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of sinovac biotech ltd and identify potential opportunities in those areas  avoid intellectual property rights related issues newspress release precision medicine how the life science industry can improve outcomes through to achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option researchers in drug rd need to better understand and manage the reams of unstructured datread more regenerative medicine market to hit  billion by  the current regenerative medicine market is worth  billion globally and will hit over  billion by  as impact of trump administrationread more  benefits of microneedlingmicroneedling hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your faceread more table of content table of contents table of contents  list of tables  list of figures  sinovac biotech ltd snapshot  sinovac biotech ltd overview  key information  key facts  sinovac biotech ltd  research and development overview  key therapeutic areas  sinovac biotech ltd  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  combination treatment modalities  sinovac biotech ltd  pipeline products glance  sinovac biotech ltd  late stage pipeline products  preregistration productscombination treatment modalities  phase iii productscombination treatment modalities  sinovac biotech ltd  clinical stage pipeline products  phase i productscombination treatment modalities  sinovac biotech ltd  early stage pipeline products  indcta filed productscombination treatment modalities  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  sinovac biotech ltd  drug profiles  enterovirus serotype  vaccine  product description  mechanism of action  rd progress  pneumococcal polysaccharide valent vaccine  product description  mechanism of action  rd progress  polio vaccine  product description  mechanism of action  rd progress  chickenpox vaccine  product description  mechanism of action  rd progress  hepatitis a  hepatitis b vaccine  product description  mechanism of action  rd progress  influenza strain ahn vaccine  product description  mechanism of action  rd progress  measles  mumps  rubella vaccine  product description  mechanism of action  rd progress  pneumococcal valent vaccine  product description  mechanism of action  rd progress  coxsackievirus serotype a vaccine  product description  mechanism of action  rd progress  diphtheria  tetanus  pertussis acellular vaccine  product description  mechanism of action  rd progress  haemophilus influenza serotype b vaccine  product description  mechanism of action  rd progress  hepatitis b vaccine  product description  mechanism of action  rd progress  human rabies vaccine  product description  mechanism of action  rd progress  meningitis vaccine  product description  mechanism of action  rd progress  rotavirus vaccine  product description  mechanism of action  rd progress  pandemic influenza vaccine  product description  mechanism of action  rd progress  sinovac biotech ltd  pipeline analysis  sinovac biotech ltd  pipeline products by route of administration  sinovac biotech ltd  pipeline products by molecule type  sinovac biotech ltd  recent pipeline updates  sinovac biotech ltd  dormant projects  sinovac biotech ltd  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of figures list of tables sinovac biotech ltd key information  sinovac biotech ltd key facts  sinovac biotech ltd  pipeline by indication   sinovac biotech ltd  pipeline by stage of development   sinovac biotech ltd  monotherapy products in pipeline   sinovac biotech ltd  combination treatment modalities in pipeline   sinovac biotech ltd  preregistration   sinovac biotech ltd  phase iii   sinovac biotech ltd  phase i   sinovac biotech ltd  indcta filed   sinovac biotech ltd  preclinical   sinovac biotech ltd  discovery   sinovac biotech ltd  pipeline by route of administration   sinovac biotech ltd  pipeline by molecule type   sinovac biotech ltd  recent pipeline updates   sinovac biotech ltd  dormant developmental projects  sinovac biotech ltd subsidiaries  list of figures sinovac biotech ltd  pipeline by top  indication   sinovac biotech ltd  pipeline by stage of development   sinovac biotech ltd  monotherapy products in pipeline   sinovac biotech ltd  combination treatment modalities in pipeline   sinovac biotech ltd  pipeline by top  route of administration   sinovac biotech ltd  pipeline by top  molecule type   please select license type single user electronic pdf   site user electronic pdf   enterprise wide electronic pdf   add to cart buy now related reports biotechnology services market global report  global pharmaceutical and biotechnology machines market research report  global biotechnology reagents market  global agricultural biotechnology market research report  global biotechnology reagents market research report  request sample mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send request discount mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send pay by wireinvoice mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  single user electronic pdf site user electronic pdf enterprise wide electronic pdf cd rom hard copy send request quote mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send market reports center  copyright  all rights reserved sinovac biotech ltd  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports sinovac biotech ltd  product pipeline review   sinovac biotech ltd  product pipeline review   wgr  september  global  pages global markets direct description table of content sample report enquiry before buy related reports sinovac biotech ltd  product pipeline review   summary global markets direct’s ‘sinovac biotech ltd  product pipeline review  ’ provides an overview of the sinovac biotech ltd’s pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by sinovac biotech ltd complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope  the report provides a snapshot of the pipeline therapeutic landscape of sinovac biotech ltd  the report provides overview of sinovac biotech ltd including its business description key facts and locations and subsidiaries  the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities  the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages  the report assesses sinovac biotech ltd’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type  the report features sinovac biotech ltd’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy  evaluate sinovac biotech ltd’s strategic position with total access to detailed information on its product pipeline  gain strategically significant competitor information analysis and insights to formulate effective rd strategies  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  identify and understand important and diverse types of therapeutics under development for sinovac biotech ltd  identify potential new clients or partners in the target demographic  plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics  devise corrective measures for pipeline projects by understanding sinovac biotech ltd’s pipeline depth and focus of pipeline therapeutics  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents table of contents  list of tables  list of figures  sinovac biotech ltd snapshot  sinovac biotech ltd overview  key facts  sinovac biotech ltd  research and development overview  key therapeutic areas  sinovac biotech ltd  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  combination treatment modalities  pipeline products  partnered products  partnered productscombination treatment modalities  sinovac biotech ltd  pipeline products glance  sinovac biotech ltd  clinical stage pipeline products  phase i productscombination treatment modalities  sinovac biotech ltd  early stage pipeline products  indcta filed productscombination treatment modalities  preclinical productscombination treatment modalities  sinovac biotech ltd  drug profiles  measles  mumps  rubella vaccine  drug profile  product description  mechanism of action  rd progress  chickenpox vaccine  drug profile  product description  mechanism of action  rd progress  coxsackievirus serotype a vaccine  drug profile  product description  mechanism of action  rd progress  diphtheria  pertussisacellular  tetanus vaccine  drug profile  product description  mechanism of action  rd progress  haemophilus influenzae b vaccine  drug profile  product description  mechanism of action  rd progress  hepatitis a  hepatitis b vaccine  drug profile  product description  mechanism of action  rd progress  hepatitis b vaccine  drug profile  product description  mechanism of action  rd progress  influenza strain ahn vaccine  drug profile  product description  mechanism of action  rd progress  polio vaccine  drug profile  product description  mechanism of action  rd progress  rabies vaccine  drug profile  product description  mechanism of action  rd progress  rotavirus vaccine  drug profile  product description  mechanism of action  rd progress  sinovac biotech ltd  pipeline analysis  sinovac biotech ltd  pipeline products by molecule type  sinovac biotech ltd  dormant projects  sinovac biotech ltd  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables sinovac biotech ltd key facts  sinovac biotech ltd  pipeline by indication   sinovac biotech ltd  pipeline by stage of development   sinovac biotech ltd  monotherapy products in pipeline   sinovac biotech ltd  combination treatment modalities in pipeline   sinovac biotech ltd  partnered products in pipeline   sinovac biotech ltd  partnered products combination treatment modalities   sinovac biotech ltd  phase i   sinovac biotech ltd  indcta filed   sinovac biotech ltd  preclinical   sinovac biotech ltd  pipeline by molecule type   sinovac biotech ltd  dormant developmental projects  sinovac biotech ltd subsidiaries  list of figures sinovac biotech ltd  pipeline by top  indication   sinovac biotech ltd  pipeline by stage of development   sinovac biotech ltd  monotherapy products in pipeline   sinovac biotech ltd  combination treatment modalities in pipeline   sinovac biotech ltd  partnered products in pipeline   sinovac biotech ltd  pipeline by molecule type   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm united states blood bag tube thermosealers market report  in this report the united states blood bag tube thermosealers market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx betwee united states hemodialysis powder solution market report  in this report the united states hemodialysis powder solution market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx betwee united states hemodialyzer market report  in this report the united states hemodialyzer market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  united states intravenous infusion pump market report  in this report the united states intravenous infusion pump market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  global veterinary vaccine market research report  in this report the global veterinary vaccine market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and   purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports united states blood bag tube thermosealers market report  published  july  united states hemodialysis powder solution market report  published  july  united states hemodialyzer market report  published  july  united states intravenous infusion pump market report  published  july  global veterinary vaccine market research report  published  july  × tell a friend about this report your name your email friends name friends email your enquiry send sinovac product pipeline news sinovac product pipeline news news provided by sinovac biotech ltd oct    et share this article beijing oct   prnewswire  sinovac biotech ltd nasdaq sva a leading provider of biopharmaceutical products in china today provided an update on the companys pipeline vaccines sabininactivated polio vaccine sipv  the company initiated the phase i clinical trial in october  the phase i trial is designed to assess the safety and tolerance of the vaccine candidates subjects include adults aged  years old young children aged  years old and infants aged two months old for a total of  volunteers the phase ii trial is expected to be launched after the preliminary results of phase i trials are available for phase ii  infants aged two months old are expected to be enrolled to select the objective dosage and assess immunogenicity with a blinded randomized and controlled design the phase ii clinical trial is expected to be completed in the third quarter of  the phase iii clinical trial is expected to assess the immunogenicity and safety with the vaccine candidate of the selected dosage from the phase ii trial sinovac originally obtained approval for sipv clinical trials in december  varicella vaccine  the company completed the phase i clinical trial in henan province with results showing that the varicella vaccine candidate has a good safety profile in the third quarter of  the company initiated the phase iii clinical trial which measures efficacy and immunogenicity with a randomized doubleblind paralleltreatment placebocontrolled study in addition to safety over  subjects aged from one to twelve years old have been enrolled as volunteers for the phase iii clinical trial sinovac obtained approval to commence human clinical trials in  mr weidong yin chairman president and ceo of sinovac commented we are pleased to provide an update on the advancement of our vaccine pipeline which underscores our strong rd capabilities and future growth prospects as we progress closer towards development and commercialization our varicella vaccine and sipv are expected to contribute to our domestic and overseas expansion efforts with our existing commercial vaccines as well as the advancement of our pipeline products we are confident sinovac will continue to expand its vaccine portfolio and overall market position about sinovac sinovac biotech ltd is a chinabased biopharmaceutical company that focuses on the research development manufacturing and commercialization of vaccines that protect against human infectious diseases sinovacs product portfolio includes vaccines against hepatitis a and b seasonal influenza hn pandemic influenza avian flu hn influenza swine flu mumps and canine rabies in  sinovac was the first company worldwide to receive approval for its hn influenza vaccine which it has supplied to the chinese governments vaccination campaign and stockpiling program the company is also the only supplier of the hn pandemic influenza vaccine to the government stockpiling program sinovacs newly developed innovative vaccine against hfmd caused by ev is ready for market launch the company is currently developing a number of new products including a sabinstrain inactivated polio vaccine pneumococcal polysaccharides vaccine pneumococcal conjugate vaccine and varicella vaccine sinovac primarily sells its vaccines in china while also exploring growth opportunities in international markets the company has exported select vaccines to mexico mongolia nepal tajikistan bangladesh chile and the philippines and was recently granted a license to commercialize its influenza vaccine in guatemala for more information please visit the companys website at wwwsinovaccom safe harbor statement this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  such statements involve known and unknown risks uncertainties and other factors that may cause our actual results levels of activity performance or achievements to differ materially from any future results levels of activity performance or achievements expressed or implied by these forward looking statements factors that might cause such a difference include our inability to compete successfully in the competitive and rapidly changing marketplace in which we operate failure to retain key employees cancellation or delay of projects and adverse general economic conditions in the united states and internationally these risks and other factors include those listed under risk factors and elsewhere in our annual report on form f as filed with the securities and exchange commission in some cases you can identify forwardlooking statements by terminology such as may will should expects intends plans anticipates believes estimates predicts potential continue or the negative of these terms or other comparable terminology although we believe that the expectations reflected in the forwardlooking statements are reasonable we cannot guarantee future results levels of activity performance or achievements the company assumes no obligation to update the forwardlooking information contained in this release sinovac biotech ltdhelen yang tel  fax  email irsinovaccom icr incbill zima us  email williamzimaicrinccom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasessinovacproductpipelinenewshtml source sinovac biotech ltd related links httpwwwsinovaccom nov    et preview sinovac announces results of  annual general meeting of shareholders oct    et preview sinovac receives clinical trial approval for varicella vaccine candidate my news release contains wide tables view fullscreen you just read sinovac product pipeline news news provided by sinovac biotech ltd oct    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search sinovac biotech ltd svao company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile sinovac biotech ltd svao related topics stocksstock screenerhealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse svao on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description sinovac biotech ltd sinovac incorporated on march   is a holding company the company is a biopharmaceutical company that focuses on the research development manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis a hepatitis b seasonal influenza haemagglutinase neuraminidase hn and influenza a hn pandemic influenza and mumps the companys pipeline consists of vaccine candidates in the clinical and preclinical development phases in china the company is engaged in the sales marketing manufacturing and development of vaccines for infectious disease the company is engaged in developing various products including healive bilive anflu panflu whole viron pandemic influenza vaccine split viron pandemic influenza vaccine panflu rabend mumps vaccine enterovirus  ev vaccine pneumococcal polysaccharide vaccine pneumococcal conjugate vaccine rubella vaccine varicella vaccine and sabin inactivated polio vaccinethe companys product healive is an inactivated hepatitis a vaccine the hepatitis a virus primarily impacts the liver by causing it to swell and preventing it from functioning properly healive is available in different doses for use by both adults approximately one milliliter per dose and children approximately  milliliter per dose the companys product bilive is a combination vaccine formulated with purified inactivated hepatitis a virus antigen and recombinant yeast hepatitis b surface antigen bilive is available in different doses for use in both adults and children the bilive vaccination schedule consists of over three doses the second dose is administered one month after the first dose and the third dose is administered approximately six months after the first dose booster vaccinations are recommended approximately five years after the initial immunizationthe companys product anflu vaccine is an inactivated split viron influenza vaccine formulated from approximately three split inactivated viron solutions the company sells anflu in mexico guatemala mongolia philippines tajikistan and bangladesh the companys product panflu is an approved vaccine available in china against the hn influenza virus the vaccine is approved for supply within china to the chinese national vaccine stockpiling program the companys product panflu is an approved vaccine against the influenza a hn virus the company was granted a production license for mumps vaccine the companys split viron pandemic influenza vaccine has been developed in conjunction with its whole viron pandemic influenza vaccine this product has been developed to address the needs of young children who may be more susceptible to adverse reactions to whole viron pandemic influenza vaccine than to a split viron vaccine the company was granted the production license of split viron pandemic influenza vaccine that is to be used among the teenagers aged from  to  the company has over seven granted patents relating to the ev vaccine in china ev vaccine primarily targets children from  months old to  years old with each child requiring a total of approximately two doses one month apart from anotherpneumococcal polysaccharide vaccine ppv is a vaccine used to prevent streptococcus pneumoniae pneumococcus infections such as pneumonia and septicemia among adults aged approximately  or older adults with serious longterm health problems smokers and children approximately two years with serious longterm health problems its neumococcal conjugate vaccine will primarily target children approximately two years old the company has completed the preclinical studies of a human vaccine against varicella varicella is a contagious infectious disease caused by the varicellazoster virus herpesvirus  human the company has completed preclinical studies and filed clinical trial application for hepatitis b vaccine the company is developing a new generation of its hepatitis ab combination vaccine based on its individual hepatitis a and b vaccinesthe company competes with kunming institute of biological product sanofi pasteur sa merck sharp  dohme corp glaxosmithkline biologicals changchun institute of biological products pukang biological co ltd changchun changsheng life sciences ltd hualan biological engineering inc aleph biological co ltd and china national biotec group co ltd » full overview of svao company address sinovac biotech ltd  shangdi xi road haidian distbeijing   bej    p f  company web links home page officers  directors name compensation weidong yin  nan wang  ming xia  simon anderson  jue lee  » more officers  directors sinovac biotech ltd news briefshandong sinobioways consortium makes an offer to take sinovac biotech private jun   briefsinovac biotech enters into agreement for goingprivate transaction jun   briefsinovac biotech announced it is delaying its annual report on form f may   briefsinovac amends shareholder rights plan mar   » more svao news related topics stocksstock screenerhealthcarepharmaceuticals sinovac biotech ltd  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report sinovac biotech ltd  product pipeline review   published by global markets direct product code  published september   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license sinovac biotech ltd  product pipeline review   published september   content info  pages description summary global markets directs sinovac biotech ltd  product pipeline review   provides an overview of the sinovac biotech ltds pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by sinovac biotech ltd complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope the report provides a snapshot of the pipeline therapeutic landscape of sinovac biotech ltd the report provides overview of sinovac biotech ltd including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses sinovac biotech ltds pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features sinovac biotech ltds outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy evaluate sinovac biotech ltds strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for sinovac biotech ltd identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding sinovac biotech ltds pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures sinovac biotech ltd snapshot sinovac biotech ltd overview key facts sinovac biotech ltd  research and development overview key therapeutic areas sinovac biotech ltd  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  partnered products partnered productscombination treatment modalities sinovac biotech ltd  pipeline products glance sinovac biotech ltd  clinical stage pipeline products phase i productscombination treatment modalities sinovac biotech ltd  early stage pipeline products indcta filed productscombination treatment modalities preclinical productscombination treatment modalities sinovac biotech ltd  drug profiles measles  mumps  rubella vaccine  drug profile product description mechanism of action rd progress chickenpox vaccine  drug profile product description mechanism of action rd progress coxsackievirus serotype a vaccine  drug profile product description mechanism of action rd progress diphtheria  pertussisacellular  tetanus vaccine  drug profile product description mechanism of action rd progress haemophilus influenzae b vaccine  drug profile product description mechanism of action rd progress hepatitis a  hepatitis b vaccine  drug profile product description mechanism of action rd progress hepatitis b vaccine  drug profile product description mechanism of action rd progress influenza strain ahn vaccine  drug profile product description mechanism of action rd progress polio vaccine  drug profile product description mechanism of action rd progress rabies vaccine  drug profile product description mechanism of action rd progress rotavirus vaccine  drug profile product description mechanism of action rd progress sinovac biotech ltd  pipeline analysis sinovac biotech ltd  pipeline products by molecule type sinovac biotech ltd  dormant projects sinovac biotech ltd  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables sinovac biotech ltd key facts sinovac biotech ltd  pipeline by indication  sinovac biotech ltd  pipeline by stage of development  sinovac biotech ltd  monotherapy products in pipeline  sinovac biotech ltd  combination treatment modalities in pipeline  sinovac biotech ltd  partnered products in pipeline  sinovac biotech ltd  partnered products combination treatment modalities  sinovac biotech ltd  phase i  sinovac biotech ltd  indcta filed  sinovac biotech ltd  preclinical  sinovac biotech ltd  pipeline by molecule type  sinovac biotech ltd  dormant developmental projects sinovac biotech ltd subsidiaries list of figures sinovac biotech ltd  pipeline by top  indication  sinovac biotech ltd  pipeline by stage of development  sinovac biotech ltd  monotherapy products in pipeline  sinovac biotech ltd  combination treatment modalities in pipeline  sinovac biotech ltd  partnered products in pipeline  sinovac biotech ltd  pipeline by molecule type  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved market report sinovac biotech ltd  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing sinovac biotech ltd  product pipeline review   aug    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs sinovac biotech ltd  product pipeline review   provides an overview of the sinovac biotech ltds pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of sinovac biotech ltds complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasereport scopethe report provides brief overview of sinovac biotech ltd including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of sinovac biotech ltds human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the sinovac biotech ltds pipeline productsreasons to get this reportevaluate sinovac biotech ltds strategic position with total access to detailed information on its product pipelineassess the growth potential of sinovac biotech ltd in its therapy areas of focusidentify new drug targets and therapeutic classes in the sinovac biotech ltds rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of sinovac biotech ltd and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of sinovac biotech ltddevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of sinovac biotech ltd and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contents list of tables list of figures sinovac biotech ltd snapshot sinovac biotech ltd overview key information key facts sinovac biotech ltd  research and development overview key therapeutic areas sinovac biotech ltd  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities sinovac biotech ltd  pipeline products glance sinovac biotech ltd  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities sinovac biotech ltd  clinical stage pipeline products phase i productscombination treatment modalities sinovac biotech ltd  early stage pipeline products indcta filed productscombination treatment modalities preclinical productscombination treatment modalities discovery productscombination treatment modalities sinovac biotech ltd  drug profiles enterovirus serotype  vaccine product description mechanism of action rd progress pneumococcal polysaccharide valent vaccine product description mechanism of action rd progress polio vaccine product description mechanism of action rd progress chickenpox vaccine product description mechanism of action rd progress hepatitis a  hepatitis b vaccine product description mechanism of action rd progress influenza strain ahn vaccine product description mechanism of action rd progress measles  mumps  rubella vaccine product description mechanism of action rd progress pneumococcal valent vaccine product description mechanism of action rd progress coxsackievirus serotype a vaccine product description mechanism of action rd progress diphtheria  tetanus  pertussis acellular vaccine product description mechanism of action rd progress haemophilus influenza serotype b vaccine product description mechanism of action rd progress hepatitis b vaccine product description mechanism of action rd progress human rabies vaccine product description mechanism of action rd progress meningitis vaccine product description mechanism of action rd progress rotavirus vaccine product description mechanism of action rd progress pandemic influenza vaccine product description mechanism of action rd progress sinovac biotech ltd  pipeline analysis sinovac biotech ltd  pipeline products by route of administration sinovac biotech ltd  pipeline products by molecule type sinovac biotech ltd  recent pipeline updates sinovac biotech ltd  dormant projects sinovac biotech ltd  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablessinovac biotech ltd key information sinovac biotech ltd key facts sinovac biotech ltd  pipeline by indication  sinovac biotech ltd  pipeline by stage of development  sinovac biotech ltd  monotherapy products in pipeline  sinovac biotech ltd  combination treatment modalities in pipeline  sinovac biotech ltd  preregistration  sinovac biotech ltd  phase iii  sinovac biotech ltd  phase i  sinovac biotech ltd  indcta filed  sinovac biotech ltd  preclinical  sinovac biotech ltd  discovery  sinovac biotech ltd  pipeline by route of administration  sinovac biotech ltd  pipeline by molecule type  sinovac biotech ltd  recent pipeline updates  sinovac biotech ltd  dormant developmental projects sinovac biotech ltd subsidiaries list of figuressinovac biotech ltd  pipeline by top  indication  sinovac biotech ltd  pipeline by stage of development  sinovac biotech ltd  monotherapy products in pipeline  sinovac biotech ltd  combination treatment modalities in pipeline  sinovac biotech ltd  pipeline by top  route of administration  sinovac biotech ltd  pipeline by top  molecule type   companies mentioned in this reportsinovac biotech ltd this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc   sinovac biotech  wikipedia sinovac biotech from wikipedia the free encyclopedia jump to navigation search sinovac biotech ltd chinese  nasdaq sva is a biopharmaceutical company that focuses on the research development manufacture and commercialization of vaccines that protect against human infectious diseases the company is based in beijing china sinovacs commercialized vaccines include healive hepatitis a bilive combined hepatitis a and b anflu influenza panflu hn and panflu hn sinovac is currently developing universal pandemic influenza vaccine and japanese encephalitis vaccine sinovac is developing vaccines for enterovirus  universal pandemic influenza japanese encephalitis and human rabies its wholly owned subsidiary tangshan yian is conducting field trials for independently developed inactivated animal rabies vaccines referencesedit  google finance urlhttpswwwgooglecomfinanceqsinovac external linksedit sinovac biotech official website v t e pharmaceutical companies of china cspc zhongrun china greatvista chemicals china nepstar guangzhou pharmaceuticals guizhentang pharmaceutical company harbin pharmaceutical group co ltd jilin aodong medicine lijun international pharmaceutical holding co ltd nanjing ange pharmaceutical north china pharmaceutical group corp shijiazhuang pharma group simcere pharmaceutical china national pharmaceutical group sinopharm group sinovac biotech tasly tongrentang yangtze river pharmaceutical group wuxi pharmatech retrieved from httpsenwikipediaorgwindexphptitlesinovacbiotecholdid categories pharmaceutical companies of chinacompanies based in beijingbiotechnology companies of chinalife sciences industryvaccine producersbiotechnology companiestechnology companies of chinahidden categories articles containing simplified chineselanguage text navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages français edit links this page was last edited on  february  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی  語   한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info sinovac biotech ltd home  english español about sinovac mission statement company history facilities strategic partners products human vaccines materials download faqs research  development rd strategy rd pipeline investor relations company profile corporate governance stock information press releases financial reports sec filings events  presentations agm summary investor kit analyst coverage investor faq contact ir newsroom press releases contact us contact us investor relations financial reports  investor kit  products  pipeline products inlive healive bilive anflu panflu panflu pipeline sinovacs rd focuses on two aspects original v press releases company news sinovac biotech ltd enters into definit sinovac biotech announces receipt of nas sinovac reports announces filing extensi sinovac amends shareholder rights plan sinovac responds to recent report  sinovac presents on “vaccine world mena  sinovac attended the third open innovati  media report congratulations inoculat  media report hn vaccine trials urged  xiaoya chen vice minister of ministry o site map contact us copyright   sinovac biotech ltd all rights reserved add no  shangdi xi road haidian district beijing prc  supported by elongtian sinovac biotech  wikipedia sinovac biotech from wikipedia the free encyclopedia jump to navigation search sinovac biotech ltd chinese  nasdaq sva is a biopharmaceutical company that focuses on the research development manufacture and commercialization of vaccines that protect against human infectious diseases the company is based in beijing china sinovacs commercialized vaccines include healive hepatitis a bilive combined hepatitis a and b anflu influenza panflu hn and panflu hn sinovac is currently developing universal pandemic influenza vaccine and japanese encephalitis vaccine sinovac is developing vaccines for enterovirus  universal pandemic influenza japanese encephalitis and human rabies its wholly owned subsidiary tangshan yian is conducting field trials for independently developed inactivated animal rabies vaccines referencesedit  google finance urlhttpswwwgooglecomfinanceqsinovac external linksedit sinovac biotech official website v t e pharmaceutical companies of china cspc zhongrun china greatvista chemicals china nepstar guangzhou pharmaceuticals guizhentang pharmaceutical company harbin pharmaceutical group co ltd jilin aodong medicine lijun international pharmaceutical holding co ltd nanjing ange pharmaceutical north china pharmaceutical group corp shijiazhuang pharma group simcere pharmaceutical china national pharmaceutical group sinopharm group sinovac biotech tasly tongrentang yangtze river pharmaceutical group wuxi pharmatech retrieved from httpsenwikipediaorgwindexphptitlesinovacbiotecholdid categories pharmaceutical companies of chinacompanies based in beijingbiotechnology companies of chinalife sciences industryvaccine producersbiotechnology companiestechnology companies of chinahidden categories articles containing simplified chineselanguage text navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages français edit links this page was last edited on  february  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sinovac biotech  wikipedia sinovac biotech from wikipedia the free encyclopedia jump to navigation search sinovac biotech ltd chinese  nasdaq sva is a biopharmaceutical company that focuses on the research development manufacture and commercialization of vaccines that protect against human infectious diseases the company is based in beijing china sinovacs commercialized vaccines include healive hepatitis a bilive combined hepatitis a and b anflu influenza panflu hn and panflu hn sinovac is currently developing universal pandemic influenza vaccine and japanese encephalitis vaccine sinovac is developing vaccines for enterovirus  universal pandemic influenza japanese encephalitis and human rabies its wholly owned subsidiary tangshan yian is conducting field trials for independently developed inactivated animal rabies vaccines referencesedit  google finance urlhttpswwwgooglecomfinanceqsinovac external linksedit sinovac biotech official website v t e pharmaceutical companies of china cspc zhongrun china greatvista chemicals china nepstar guangzhou pharmaceuticals guizhentang pharmaceutical company harbin pharmaceutical group co ltd jilin aodong medicine lijun international pharmaceutical holding co ltd nanjing ange pharmaceutical north china pharmaceutical group corp shijiazhuang pharma group simcere pharmaceutical china national pharmaceutical group sinopharm group sinovac biotech tasly tongrentang yangtze river pharmaceutical group wuxi pharmatech retrieved from httpsenwikipediaorgwindexphptitlesinovacbiotecholdid categories pharmaceutical companies of chinacompanies based in beijingbiotechnology companies of chinalife sciences industryvaccine producersbiotechnology companiestechnology companies of chinahidden categories articles containing simplified chineselanguage text navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages français edit links this page was last edited on  february  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view